MicroPort NeuroScientific Corporation engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. The company offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; NUMEN Silk; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; Comaneci, an adjustable temporary coil embolization device; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. It also offers NeuroGuard and NuFairy, an absorbable coil embolization system; and a liquid embolic agent for cerebral arteriovenous malformations. In addition, the company provides APOLLO, an intracranial stent, and a balloon-expandable stent to treat intracranial atherosclerotic disease; Bridge, a rapamycin-target eluting vertebral artery stent system; and Diveer, an intracranial balloon catheter to treat cerebral atherosclerosis stenosis. Further, it offers Neurohawk, a stent thrombectomy device; X-Track, a distal access catheter; Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke; WAVE track, an intracranial aspiration catheter; and a balloon protection guide catheter. Additionally, the company provides a Carotid Stent System, neurovascular guidewires, and U-track support catheter. Furthermore, it offers a Fastrack Microcatheter System, Veyronwire Neurovascular Guide Wire, 17 Microcatheter, Distal Protection Device, and a QUEEN-track Microcatheter, a hydrophilic coating device for the stimulation of blood vessels. The company was formerly known as MicroPort NeuroTech Limited and changed its name to MicroPort NeuroScientific Corporation in August 2024. MicroPort NeuroScientific Corporation was founded in 2004 and is headquartered in Shanghai, the People's Republic of China.